Molecular characterization of resistance to rifampicin in clinical isolates of Neisseria meningitidis

Clin Microbiol Infect. 2009 Dec;15(12):1178-81. doi: 10.1111/j.1469-0691.2009.02783.x. Epub 2009 May 16.

Abstract

Among 3904 meningococcal isolates collected between October 2002 and June 2007 by the French Meningococcal Reference Centre, eight (0.20%) were resistant to rifampicin (Rif-R; MIC >1 mg/L) and 27 (0.69%) were intermediate-resistant to rifampicin (Rif-I; MICs between 0.38 mg/L and 1 mg/L) according to the E-test method. The MICs determined by agar dilution were lower, eliminating the E-test intermediate category. All Rif-R isolates had mutations in the rpoB gene, resulting in substitutions at or near amino acid position 552, which were absent in non-resistant isolates. These data suggest that a rifampicin clinical breakpoint of 1.0 mg/L should be adopted for Neisseria meningitidis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • DNA-Directed RNA Polymerases / genetics
  • Drug Resistance, Bacterial / genetics*
  • Humans
  • Meningococcal Infections / microbiology*
  • Microbial Sensitivity Tests / standards
  • Mutation
  • Neisseria meningitidis / classification
  • Neisseria meningitidis / drug effects*
  • Neisseria meningitidis / genetics
  • Neisseria meningitidis / isolation & purification
  • Rifampin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • DNA-Directed RNA Polymerases
  • RNA polymerase beta subunit
  • Rifampin